Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 110

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 110
---
 standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third -partyestimates and other business data, including assumptions and estimates relating to our ability to generate revenue from the development of new workflows. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. Consequently, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from our products and services, including our research services may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our products and services is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and growth prospects. 29 We have a history of losses, and we may not be able to achieve or sustain profitability. The Company has historically incurred significant losses: $1,322,306, $4,516,095 and $1,291,932 for the six months ended December31, 2024, and for the fiscal years ended June 30, 2024 and 2023, respectively. The Company has also recorded accumulated deficits of $8,263,789, $6,941,483 and $3,588,427 as of December31, 2024, June 30, 2024 and 2023, respectively. Additionally, the Company’s recurring cash outflows from operations amounted to $1,022,381, $1,885,895 and $1,306,705 for the six months ended December31, 2024 and for the years ended June 30, 2024 and 2023. Historically, we have devoted most of our financial resources to the research and development of our clinical genetics products and services, as well as to develop Rewell, our preventative health business. The discovery and development of safe and effective healthcare is a complex and uncertain process, which takes many years and involves significant costs.